Friday, July 10, 2026

pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)

Amgen

Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec

One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
One Amgen Center Drive, Thousand Oaks, CA 91320, US
Founded
1980
Employees
40,212
Programs
96
Drugs
124
Patents
25
Clinical program

20160323

Phase 1 · other · Small Cell Lung Cancer

20160323 for Small Cell Lung Cancer is a Phase 1 program (other) at Amgen with 1 ClinicalTrials.gov record(s).

← All Amgen projects Phase 1 other active

Internal code 20160323

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Amgen
Phase
Phase 1
Modality
other
Indication
Small Cell Lung Cancer
Status
active
Trials
1